Rothschild & Co Asset Management US’s Vanda Pharmaceuticals VNDA Stock Holding History

Rothschild & Co Asset Management US’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-442,769	Closed	-$7.27M	–	367
2019 Q4	$7.27M	Sell	442,769 -20,139	-4%	-$304K	0.08%	270
2019 Q3	$6.15M	Sell	462,908 -4,304	-0.9%	-$60K	0.07%	275
2019 Q2	$6.58M	Buy	467,212 +45,071	+11%	+$717K	0.07%	276
2019 Q1	$7.77M	Sell	422,141 -43,413	-9%	-$989K	0.08%	269
2018 Q4	$12.2M	Buy	465,554 +23,738	+5%	+$558K	0.15%	227
2018 Q3	$10.1M	Sell	441,816 -8,205	-2%	-$168K	0.1%	267
2018 Q2	$8.57M	Sell	450,021 -902,555	-67%	-$15.1M	0.09%	276
2018 Q1	$22.8M	Sell	1,352,576 -19,515	-1%	-$327K	0.25%	166
2017 Q4	$20.9M	Buy	1,372,091 +59,757	+5%	+$887K	0.22%	185
2017 Q3	$23.5M	Buy	+1,312,334	New	+$22M	0.26%	167

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Rothschild & Co Asset Management US's VNDA Position: Q1 2020 in Review

Rothschild & Co Asset Management US sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 442,769 shares — an estimated $7.27M sold.

Rothschild & Co Asset Management US first reported a position in VNDA in Q3 2017 and held it in 10 quarters. The position peaked at $23.5M in Q3 2017. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

Rothschild & Co Asset Management US reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Rothschild & Co Asset Management US sold 442,769 Vanda Pharmaceuticals shares in Q1 2020, an estimated $7.27M.
Rothschild & Co Asset Management US first reported a position in Vanda Pharmaceuticals in Q3 2017 and held it in 10 quarters.
Rothschild & Co Asset Management US's Vanda Pharmaceuticals position peaked at $23.5M in Q3 2017.
159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2020, filed 14 May 2020.